<DOC>
	<DOCNO>NCT00157729</DOCNO>
	<brief_summary>The purpose study determine whether MC-1 alone combination ACE inhibitor effective reduce blood pressure metabolic dysfunction associate diabetes</brief_summary>
	<brief_title>MATCHED ( MC-1 ACE Therapeutic Combination Hypertensive Diabetics )</brief_title>
	<detailed_description>Hypertension extremely common co-morbid condition diabetic , affect 11 million patient , depend obesity , ethnicity age . Hypertension substantially increase risk macrovascular microvascular complication include stroke , coronary artery disease , peripheral vascular disease , retinopathy , nephropathy possibly neuropathy . In recent year , adequate data well-designed randomized clinical trial demonstrate effectiveness aggressive treatment hypertension reduce diabetic complication . In epidemiological UK Prospective Diabetes Study ( UKPDS ) , 10 mmHg decrease mean systolic blood pressure associate reduction risk 12 % complication relate diabetes , 15 % death relate diabetes , 11 % myocardial infarction 13 % microvascular complication . Currently consensus guideline recommend blood pressure target &lt; 130/80 mmHg diabetic patient hypertension , even though recognize many people require three drug reach goal . MC-1 naturally occur metabolite vitamin B6 , thus low toxicity . Evidence pre-clinical study suggest MC-1 beneficial effect hypertension metabolic dysfunction . This trial ass effect MC-1 alone MC-1 combination ACE inhibitor compare placebo hypertension parameter metabolic function type 2 diabetic patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Pyridoxal Phosphate</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>Type 2 diabetes mellitus treat diet , oral hypoglycaemic agent insulin ) minimum 2 year ( 24 month ) Systolic hypertension prior entry washout period . At Visit 3 patient must mean sit systolic blood pressure range 140180 mmHg , mean sit diastolic blood pressure &lt; 110mmHg A mean daytime ambulatory systolic blood pressure great equal 135 mm Hg baseline Poorly control type 2 diabetes mellitus ( HbA1c ≥ 10 % ) Secondary hypertension aetiology , renal artery stenosis , coarctation aorta pheochromocytoma History malignant hypertension Body mass index &gt; 37 Single function kidney Known sensitivity intolerance angiotensinconverting enzyme inhibitor History angioedema Known syncopal disorder Pregnant woman woman childbearing potential sexually active use appropriate method birth control ( double barrier oral contraceptive ) Concomitant therapy antihypertensive medication , include use indication hypertension ( e.g. , diuretic reason , minoxidil hair loss , propranolol HCl migraine , terazosin HCl benign prostatic hyperplasia , 5phosphodiesterase inhibitor ( Viagra , Cialis , Levitra ) within 48 hour clinic visit , ACEinhibitors congestive heart failure , agent could cause change blood pressure ) , except stable dos NSAIDs , tricyclic agent take bedtime . Patients unwilling discontinue medication patient Investigator feel clinically inappropriate discontinue medication participate study Concomitant therapy lithium and/or major psychotropic agent phenothiazine Concomitant therapy oral steroid ACTH Concomitant therapy cold and/or flu medication contain sympathomimetic agent . Intermittent use therapy contain ephedrine permit except within 72 hour clinic visit mean trough SiSBP Concomitant therapy vitamin supplement may contain pyridoxine pyridoxine derivative pyridoxal phosphate pyridoxal Hypertension induce oral contraceptive . Replacement hormone ( thyroid , testosterone , estrogens ) permit patient stable dose least three month Existing symptomatic cerebrovascular disease include previous transient ischemic attack ( TIA ) stroke within 12 month prior screen Myocardial infarction , percutaneous coronary intervention coronary artery bypass surgery within 6 month prior screen Clinically significant AV conduction disturbance , i.e. , second third degree AV block , sick sinus syndrome clinically significant bradycardia ( rest heart rate &lt; 60 beats/minute ) without permanent pacemaker Presence atrial flutter atrial fibrillation Potentially lifethreatening ventricular arrhythmia , decompensated valvular disease , presence hemodynamically significant obstructive valvular disease , cardiomyopathy Serum potassium &lt; 3.5 &gt; 5.5 mEq/L The presence severe hepatic impairment manifest AST ( SGOT ) &gt; 2.5 time upper limit normal ALT ( SGPT ) &gt; 2.5 time upper limit normal Any clinically significant laboratory value Investigator ’ judgement could clinically significant outcome study . This include , limited , hematocrit , haemoglobin platelet count Any moderate severe renal impairment , manifest serum creatinine 200 micromol/L A history clinically important gastrointestinal resection , malabsorption cirrhosis liver Any concurrent severe disease , Investigator ’ judgement , could preclude participation survival Use investigational drug device , participation drug study within 30 day prior baseline Inability take current antihypertensive medication Unwillingness inability give consent follow protocol procedure Arm circumference great 41 cm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>antihypertensive agent</keyword>
	<keyword>diabetes mellitus type 2</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>